{"id":"ct-p17-sc-ai-adalimumab","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Injection site reactions"},{"rate":"15-25","effect":"Upper respiratory tract infections"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Nausea"},{"rate":"1-3","effect":"Serious infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adalimumab is a fully human monoclonal antibody that binds to and neutralizes TNF-α, a key pro-inflammatory cytokine. By inhibiting TNF-α signaling, it suppresses the inflammatory cascade underlying autoimmune and inflammatory diseases. CT-P17 SC AI is Celltrion's subcutaneous formulation of this established mechanism, designed for improved patient convenience.","oneSentence":"CT-P17 SC AI is a subcutaneous adalimumab biosimilar that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:01.107Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Plaque psoriasis"}]},"trialDetails":[{"nctId":"NCT04171414","phase":"PHASE3","title":"A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2019-09-09","conditions":"Rheumatoid Arthritis","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CT-P17 SC AI (adalimumab)","genericName":"CT-P17 SC AI (adalimumab)","companyName":"Celltrion","companyId":"celltrion","modality":"Biologic","firstApprovalDate":"","aiSummary":"CT-P17 SC AI is a subcutaneous adalimumab biosimilar that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}